Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)

Blood

Volumn 114, Issue 9, 2009, Pages 1736-1745

  Borrello, Ivan M ^a   Levitsky, Hyam I ^a   Stock, Wendy ^b   Sher, Dorie ^b   Qin, Lu ^a   DeAngelo, Daniel J ^c   Alyea, Edwin P ^c   Stone, Richard M ^c   Damon, Lloyd E ^d   Linker, Charles A ^d   Maslyar, Daniel J ^e   Hege, Kristen M ^e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CELL GENESYS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL GENE; CELL STRAIN K 562; CELL THERAPY; CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; HUMAN; HYPERSENSITIVITY REACTION; LEUKEMIA CELL; LUPUS ERYTHEMATOSUS CELL TEST; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; AUTOTRANSPLANTATION; DISEASE FREE SURVIVAL; FEMALE; IMMUNOTHERAPY; MALE; METHODOLOGY; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; REMISSION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TUMOR CELL LINE;

ADULT; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 70349242210     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-205278     Document Type: Article

References (37)

1. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. N Engl J Med. 1994;331:896-903.
2. Linker C, Ries C, Damon L, et al. Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biol Blood Marrow Transplant. 2000;6:50-57.
3. Linker C, Ries C, Damon L, Rugo H, Wolf J. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood. 1993;81:311-318. (Pubitemid 23027144)
4. Farag S, Ruppert A, Mrózek K, et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol. 2005;23:482-493. (Pubitemid 46224225)
5. Cassileth P, Harrington D, Appelbaum F, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649-1656. (Pubitemid 28550689)
6. Baer MR, George SL, Caligiuri MA, et al. Low dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol. 2008;26:4934-4939.
7. Brune M, Castaigne S, Catalona W, et al. Improved leukemia-free survival after post-consolidation treatment with histamine dihydrochloride and interleukin-2 in AML: a randomized phase III trial. Blood. 2004;104:261a.
8. Harousseau J, Cahn J, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia: The Groupe Ouest Est Leucemis Aigues Myeloblastiques (GOELAM). Blood. 1997;90:2978-2986.
9. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood. 2003;102:1232-1240.
10. Zittoun R, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia: European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995;332:217-223.
11. Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol. 2003;21:3343-3350. (Pubitemid 46606268)
12. Salgia R, Lynch T, Skarin A, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003;21:624-630. (Pubitemid 46621895)
13. Nemunaitis J, Jahan T, Ross H, et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced stage non-small cell lung cancer. Cancer Gene Ther. 2006;13:555-562. (Pubitemid 43756243)
14. Laheru D, Lutz E, Burke J, et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res. 2008;14:1455-1463.
15. Jaffee E, Hruban R, Laheru D, et al. Novel allogeneic GM-CSF-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001;19:145-156.
16. Higano C, Corman J, C. SD, et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic cellular immunotherapy for metastatic hormone-refractory prostate cancer. Blood. 2008; 113:975-984.
17. Small EJ, Sacks N, Nemunaitis J, et al. Granulocyte macrophage colony-stimulating factor- secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res. 2007;13:3883-3891. (Pubitemid 47037595)
18. Simons JW, Carducci MA, Mikhak B, et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res. 2006;12:3394-3401.
19. Nemunaitis J, Smith J, Sterman D, et al. A phase I/II trial of bystander GVAX cancer vaccine in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2002;21:13a.
20. Hege KM, Jooss K, Pardoll D. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int Rev Immunol. 2006;25:321-352. (Pubitemid 44972270)
21. Borrello I, Biedrzyki B, Sheets N, et al. Autologous tumor combined with a GM-CSF-secreting cell line vaccine (GVAX) following autologous stem cell transplant (ASCT) in multiple myeloma. Blood. 2004;104:129a.
22. Borrello I, Sotomayor E, Cooke S, Levitsky H. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther. 1999;10:1983-1991. (Pubitemid 29387912)
23. Borrello I, Sotomayor E, Rattis F, Cooke S, Gu L, Levitsy H. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulation factor. Blood. 2000;95:3011-3019.
24. Cilloni D, Gottardi E, De Micheli D, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia. 2002;16:2115-2121. (Pubitemid 35203456)
25. Ostergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients: results from a single-centre study. Br J Haematol. 2004; 125:590-600. (Pubitemid 38747961)
26. Cilloni D, Messa F, Arruga F, et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica. 2008;93:921-924. (Pubitemid 351821731)
27. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-4336. (Pubitemid 35429670)
28. Serafini P, Carbley R, Noonan K, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Can Res. 2004;64:6337-6343. (Pubitemid 39129439)
29. Gunn N, Damon L, Varosy P, et al. High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for AML. Biol Blood Marrow Transplant. 2003;9:643-648.
30. Meloni G, Diverio D, Vignetti M, et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood. 1997;90:1321-1325. (Pubitemid 27314172)
31. de Botton S, Fawaz A, Chevret S, et al. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol. 2005; 23:120-126. (Pubitemid 41702630)
32. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28-37. (Pubitemid 43990609)
33. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432. (Pubitemid 37211057)
34. Cavé H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia: European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med. 1998;339:591-598.
35. Dworzak M, Fröschl G, Printz D, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002;99: 1952-1958. (Pubitemid 34525474)
36. Ogawa H, Tamaki H, Ikegame K, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood. 2003;101:1698-1704. (Pubitemid 36237562)
37. Dührsen U, Villeval J, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood. 1998;72:2074-2081.